Seyfettin Erdem

Dr. Seyfettin Erdem

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
LHLeyla Hazar
Leyla Hazar
MKMine Karahan
Mine Karahan
EVEsra Vural
Esra Vural
SASedat Ava
Sedat Ava
SESeyfettin Erdem
Seyfettin Erdem
UKUğur Keklikçi
Uğur Keklikçi

27 April 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
MKMine Karahan
Mine Karahan
ADAtılım Armağan Demirtaş
Atılım Armağan Demirtaş
LHLeyla Hazar
Leyla Hazar
SESeyfettin Erdem
Seyfettin Erdem
SASedat Ava
Sedat Ava
UKUğur Keklikçi
Uğur Keklikçi

4 July 2020 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
SESeyfettin Erdem
Seyfettin Erdem
MKMine Karahan
Mine Karahan
SASedat Ava
Sedat Ava
ZPZafer Pekkolay
Zafer Pekkolay
ADAtilim Armagan Demirtas
Atilim Armagan Demirtas
UKUgur Keklikci
Ugur Keklikci

7 June 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
SESeyfettin Erdem
Seyfettin Erdem
MKMine Karahan
Mine Karahan
SASedat Ava
Sedat Ava
MDMehmet Emin Dursun
Mehmet Emin Dursun
LHLeyla Hazar
Leyla Hazar
UKUgur Keklikci
Ugur Keklikci

1 January 2021 in Therapeutic Advances in Ophthalmology
Verified
Journal Article
Open access
PDF file
MKMine Karahan
Mine Karahan
LHLeyla Hazar
Leyla Hazar
SESeyfettin Erdem
Seyfettin Erdem
SASedat Ava
Sedat Ava
MDMehmet Emin Dursun
Mehmet Emin Dursun
UKUğur Keklikçi
Uğur Keklikçi
We aimed to analyze blood inflammation parameters in patients with age-related macular degeneration (AMD). In this retrospective study, patients were divided into three groups: wet-type AMD (n = 60), dry-type AMD (n = 60), and healthy controls (n = 71). The laboratory and demographic data of the patients were analyzed. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were calculated manually. The mean NLR was 2.26 ± 1.42 in the dry-type AMD group, 3.90 ± 1.65 in the wet-type AMD group, and 1.84 ± 0.61 in the control group (p < 0.001). The mean MLR was 0.30 ± 0.20 in the dry-type AMD group, 0.47 ± 0.31 in the wet-type AMD group, and 0.28 ± 0.14 in the control group (p < 0.001). The mean PLR was 129.31 ± 79.82 in the dry-type AMD group, 156.67 ± 83.99 in the wet-type AMD group, and 135.59 ± 58.68 in the control group (p = 0.101). Receiver operating characteristic (ROC) curve analyses revealed that the area under the curve (AUC) for NLR and MLR was 0.920 and 0.717, respectively, for wet-type AMD. The sensitivity and specificity of NLR for wet-type AMD were 64% and 93%, respectively, whereas MLR was 63% and 75%, respectively. Simple blood tests revealed that NLR and MLR were significantly higher in patients with wet-type AMD than in patients with dry-type AMD and healthy controls, which implies low-grade inflammation.

1 November 2021 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
MKM. Karahan
M. Karahan
SESeyfettin Erdem
Seyfettin Erdem
SAS. Ava
S. Ava
AKA.A. Kaya
A.A. Kaya
ADA.A. Demirtas
A.A. Demirtas
UKU. Keklikci
U. Keklikci